20.77
6.74%
-1.50
Dianthus Therapeutics Inc stock is traded at $20.77, with a volume of 191.79K.
It is down -6.74% in the last 24 hours and down -28.50% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$22.27
Open:
$22.09
24h Volume:
191.79K
Relative Volume:
0.81
Market Cap:
$614.73M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-51.44M
1W Performance:
-21.18%
1M Performance:
-28.50%
6M Performance:
-18.42%
1Y Performance:
+78.74%
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
857-201-2700
Address
300 TECHNOLOGY SQUARE, CAMBRIDGE
Compare DNTH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
DNTH | 20.77 | 614.73M | 4.12M | -56.68M | -51.44M | 0.00 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-26-24 | Initiated | Robert W. Baird | Outperform |
Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
May-16-24 | Initiated | H.C. Wainwright | Buy |
Feb-15-24 | Initiated | Stifel | Buy |
Dec-26-23 | Initiated | Jefferies | Buy |
Nov-22-23 | Initiated | Wedbush | Outperform |
Oct-30-23 | Initiated | Guggenheim | Buy |
Sep-28-23 | Initiated | Raymond James | Outperform |
Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
Aug-20-21 | Resumed | Goldman | Neutral |
Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-22-21 | Reiterated | B. Riley Securities | Buy |
Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
Jun-15-21 | Initiated | BTIG Research | Buy |
May-18-21 | Initiated | B. Riley Securities | Buy |
Jan-07-21 | Initiated | Mizuho | Buy |
Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates - MSN
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1%Should You Sell? - MarketBeat
What is HC Wainwright's Estimate for DNTH FY2024 Earnings? - MarketBeat
Raymond James Forecasts Strong Price Appreciation for Dianthus Therapeutics (NASDAQ:DNTH) Stock - Defense World
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts - Benzinga
Dianthus Therapeutics' (DNTH) Buy Rating Reiterated at HC Wainwright - MarketBeat
Oppenheimer Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
Dianthus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up After Analyst Upgrade - Defense World
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $56.00 - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap UpHere's Why - MarketBeat
Dianthus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dianthus Therapeutics Reports Q3 Progress and Financials - TipRanks
Dianthus Therapeutics Reports $342.6M Cash Runway, Advances Phase 3 CIDP Trial Plans | DNTH Stock News - StockTitan
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Analysts - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Analysts - MarketBeat
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - The Manila Times
Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
SG Americas Securities LLC Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5%Should You Buy? - MarketBeat
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting - The Manila Times
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4%Here's What Happened - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $45.13 Consensus Target Price from Brokerages - MarketBeat
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength? - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.5% – Still a Buy? - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 4.5%Should You Buy? - MarketBeat
Dianthus: Modest Opportunity With 2 Caveats (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.7%Here's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume – Still a Buy? - Defense World
Marshall Wace LLP Sells 4,731 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity - MSN
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity (NASDAQ:DNTH) - Seeking Alpha
Oppenheimer Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down to $27.88 - Defense World
Renaissance Technologies LLC Lowers Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
American Century Companies Inc. Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Fred Alger Management LLC Has $163,000 Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Rating Reiterated by HC Wainwright - MarketBeat
Expert Ratings For Dianthus Therapeutics - Benzinga
Point72 Asia Singapore Pte. Ltd. Acquires 29,159 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Point72 Asia Singapore Pte. Ltd. Has $1.02 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 40,831 Shares of Stock - Defense World
Dirk Kersten Sells 79,411 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock - Defense World
Logos Global Management LP Sells 1,465,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Shares Down 3% - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Holdings Boosted by Great Point Partners LLC - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):